DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
05/12/2023* 08:30 EST Earnings Call Q1 2023 -- -- --
05/12/2023* -- Results Q1 2023 -- -- --
02/28/2023 08:30 EST Earnings Call Q4 2022 -- -- --
02/28/2023 -- Results Q4 2022 -0.44 -0.54 17.91%
11/10/2022 08:30 EST Earnings Call Q3 2022 -- -- --
11/10/2022 -- Results Q3 2022 -0.48 -0.51 5.42%
08/11/2022 -- Results Q2 2022 -0.42 -0.50 15.15%
08/11/2022 08:30 EST Earnings Call Q2 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 05/12/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 02/28/2023
Beat/Miss Upgrade
Return Since -66.80%
Last FQE 12/31/2022
Next FQE 03/31/2023

Profile

Edit
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
URL https://www.altimmune.com
Investor Relations URL https://ir.altimmune.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 12, 2023 (est.)
Last Earnings Release Feb. 28, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jan. 20, 2017

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date Jan. 20, 2017
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Annual Total Returns Versus Peers

Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
71.05%
-88.48%
-96.55%
-8.25%
496.8%
-18.79%
79.59%
-74.59%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
2.96%
-28.90%
102.8%
96.14%
18.24%
32.12%
-47.18%
43.90%
-0.56%
-61.02%
76.34%
-50.00%
170.7%
368.6%
-63.48%
-37.74%
20.29%
-34.00%
-7.04%
-33.16%
-14.33%
110.1%
-29.79%
-58.19%
0.00%
-65.10%
241.2%
88.42%
4.84%
-29.80%
-18.29%
104.3%
1.91%
As of March 22, 2023.

Profile

Edit
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
URL https://www.altimmune.com
Investor Relations URL https://ir.altimmune.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 12, 2023 (est.)
Last Earnings Release Feb. 28, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jan. 20, 2017

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ALT Tweets